Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Bolt Biotherapeutics, Inc. (BOLT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update – First patients dosed in the BDC-1001 Phase 2 program – BDC-1001 Phase 1 data presented at ASCO 2023 demonstrated favorable safety profile and encouraging efficacy as a monotherapy and in combination with nivolumab in HER2-expressing tumors – BDC-3042 received IND clearance; clinical trial expected to start before year-end – Cash balance of $157.1 million anticipated to fund key milestones through 2025 REDWOOD CITY, Calif., August 7, 2023"
05/11/2023 8-K Quarterly results
Docs: "Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update – Comprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO 2023 – BDC-1001 Phase 2 program expected to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer – Cash balance of $171.0 million anticipated to fund key clinical milestones through 2025 REDWOOD CITY, Calif., May 11, 2023"
11/10/2022 8-K Quarterly results
Docs: "Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update – BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022 – BDC-3042 on track to enter the clinic in 2023; new preclinical data at SITC 2022 – Cash balance of $209.6 million anticipated to fund key milestones through 2025 REDWOOD CITY, Calif, Nov. 10, 2022"
08/10/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/30/2022 8-K Quarterly results
Docs: "Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights – BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in 2022; BDC-1001 combination study arm with OPDIVO® progressing well – Preclinical data on multiple pipeline programs will be presented at AACR 2022, including BDC-2034, BDC-3042, and a PD-L1 ISAC – Cash balance of $272 million expected to fund key milestones and operations into 2024 REDWOOD CITY, CA, March 30, 2022 – Bolt Biotherapeutics, Inc. a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, toda..."
11/09/2021 8-K Quarterly results
Docs: "Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights –BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021"
08/12/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy